[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Mulet-Margalef et al., 2023 - Google Patents

Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape

Mulet-Margalef et al., 2023

View HTML
Document ID
8454415081256376900
Author
Mulet-Margalef N
Linares J
Badia-Ramentol J
Jimeno M
Sanz Monte C
Manzano Mozo J
Calon A
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Between 5% and 15% of colorectal cancers (CRC) show deficiencies in the mismatch repair machinery and high microsatellite instability (dMMR/MSI-H). dMMR/MSI- H CRC is characterized by a dysfunctional DNA repair system, which renders the tumor …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Takei et al. The new era of immunotherapy in gastric cancer
Mulet-Margalef et al. Challenges and therapeutic opportunities in the dMMR/MSI-H colorectal cancer landscape
Lichtenstern et al. Immunotherapy, inflammation and colorectal cancer
Taieb et al. Adjuvant chemotherapy for stage III colon cancer
Boyero et al. Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy
Passardi et al. Immune checkpoints as a target for colorectal cancer treatment
Cesano et al. Bringing the next generation of immuno-oncology biomarkers to the clinic
Copija et al. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients
Wojas-Krawczyk et al. Beyond PD-L1 markers for lung cancer immunotherapy
Pagni et al. Targeting immune-related biological processes in solid tumors: we do need biomarkers
Singh et al. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy
Vallilas et al. Gastrointestinal stromal tumors (GISTs): novel therapeutic strategies with immunotherapy and small molecules
Kim et al. Current status and future perspectives of checkpoint inhibitor immunotherapy for prostate cancer: a comprehensive review
Tunger et al. The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy
Zhang et al. Precision immuno-oncology: prospects of individualized immunotherapy for pancreatic cancer
Otoshi et al. Possible biomarkers for cancer immunotherapy
Huyghe et al. Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine
Palicelli et al. What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review (part 6): correlation of PD-L1 expression with the status of mismatch repair system, BRCA, PTEN, and other genes
Fugazzola et al. Intratumoral genetic heterogeneity in papillary thyroid cancer: occurrence and clinical significance
Rebuzzi et al. Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives
Ros et al. Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers
Iivanainen et al. Possibilities of improving the clinical value of immune checkpoint inhibitor therapies in cancer care by optimizing patient selection
Pinto et al. Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives
Li et al. Programmed death ligand 1 indicates pre-existing adaptive immune response by tumor-infiltrating CD8+ T cells in non-small cell lung cancer
Sesma et al. From tumor mutational burden to blood T cell receptor: looking for the best predictive biomarker in lung cancer treated with immunotherapy